It is our pleasure to announce the 17th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy, to be held 18 - 20 May 2016 in Washington DC, USA (t.b.c.).
Understanding the clinical pharmacology of antiretroviral therapy is pivotal to designing optimal treatment and prevention strategies for HIV & Hepatitis infection. Drug exposure is significantly influenced by drug interactions, medication taking behavior, and patients’ physiologic and genetic characteristics. These factors are central to determining therapeutic efficacy, failure or toxicity. Despite great progress, many pharmacologic challenges still exist.
The International Workshop on Clinical Pharmacology of HIV Therapy and the International Workshop on Clinical Pharmacology of Hepatitis Therapy have always addressed these challenges for HIV and Hepatitis separately. Over the years, both meetings have become the premier international workshop on clinical pharmacology in their field. In 2014 these two workshops have joined their forces, very succesfully.
The 17th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy will provide a platform for state-of-the-art discussions of current topics fundamental to the optimal use of antiretroviral therapy including drug-drug interactions, pharmacokinetics of investigational agents and existing drugs, pharmacodynamics, drug dosing in special populations, post-marketing surveillance project, and regulatory considerations.
The Clinical Pharmacology workshop is a unique platform where industry pharmacologist and academic pharmacologists sharing and discussing the latest developments in clinical pharmacology. Improved knowledge on drug efficacy/toxicity and potential drug interactions enables clinicians to further optimize antiviral treatment for their HIV and/or Hepatitis infected patients.
We look forward to welcoming you to Washington DC, USA in May 2016!
The Organizing Committee